The inhibition of amyloid fibrillation using the proteolytic products of PQQ-modified α-synuclein

Open Biotechnology Journal

Volumn 3, Issue , 2009, Pages 40-45

  Kobayashi, Natsuki ^a   Kim, Jihoon ^a   Ikebukuro, Kazunori ^a   Sode, Koji ^a,b  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b NONE   (Japan)

Author keywords

synuclein; Amyloid fibril; Inhibitor; Parkinson's disease; Peptide; Pyrroloquinoline quinone

Indexed keywords

AMYLOID FIBRIL; AMYLOID FORMATION; COFACTOR; INHIBITOR; INHIBITORY EFFECT; NEURODEGENERATIVE DISEASE; OXIDATIVE METABOLISM; PARKINSON'S DISEASE; PEPTIDE FRAGMENTS; PYRROLOQUINOLINE QUINONE; SEQUENCE-DEPENDENT; SPECIFIC INTERACTION; SYNUCLEIN;

GLYCOPROTEINS; POLYPEPTIDES;

AMINES;

ALPHA SYNUCLEIN; AMYLOID; PEPTIDE FRAGMENT; PYRROLOQUINOLINEQUINONE;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION;

BACTERIA (MICROORGANISMS);

EID: 77953396159     PISSN: None     EISSN: 18740707     Source Type: Journal    
DOI: 10.2174/1874070700903010040     Document Type: Article

References (16)

1. Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord 2005; 20: (Suppl) S37-44. (Pubitemid 41419553)
2. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314(5800): 777-781
3. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 2003; 40(3): 453-456 (Pubitemid 37494695)
4. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443(7113): 774-779 (Pubitemid 44622681)
5. Ono K, Yamada M. Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases. Neurobiol Dis 2007; 25(2): 446-454
6. Ono K, Yamada M. Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97(1): 105-115
7. Masuda M, Suzuki N, Taniguchi S, et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 2006; 45(19): 6085-6094 (Pubitemid 43727101)
8. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 2004; 18(9): 962-964 (Pubitemid 39561492)
9. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 2004; 11(11): 1513-1521 (Pubitemid 39527278)
10. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001; 294(5545): 1346-1349
11. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 2004; 279(26): 26846-26857 (Pubitemid 38812518)
12. Kobayashi M, Kim J, Kobayashi N, et al. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 2006; 349(3): 1139-1144 (Pubitemid 44380214)
13. Rochet JC, Lansbury PT, Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000; 10(1): 60-68
14. Naiki H, Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab Invest 1996; 74(2): 374-383 (Pubitemid 26072080)
15. Harper JD, Lansbury PT, Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997; 66: 385-407.
16. Estrada LD, Soto C. Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des 2006; 12(20): 2557-2567